利妥昔单抗、泽布替尼与维奈克拉联合治疗弥漫性大B细胞淋巴瘤的疗效观察  

Observational study on the efficacy of rituximab,zanubrutinib,and venetoclax combination therapy for diffuse large B-cell lymphoma

作　　者：苏于泰 雒雪萍 付珊[2] 李奕[2] 李婧文 郑伟燕[2] 马平[1] 王海军[1] Su Yutai;Luo Xueping;Fu Shan;Li Yi;Li Jingwen;Zheng Weiyan;Ma Ping;Wang Haijun(Emergency Department,Children’s Hospital Affiliated to Zhengzhou University,Henan Children’s Hospital,Zhengzhou Children’s Hospital,Zhengzhou 450000;Bone Marrow Transplantation Center,the First Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310000)

机构地区：[1]郑州大学附属儿童医院河南省儿童医院郑州儿童医院急诊科,河南郑州450000 [2]浙江大学医学院附属第一医院骨髓移植中心,浙江杭州310000

出　　处：《中国现代医药杂志》2025年第3期8-13,共6页Modern Medicine Journal of China

基　　金：河南省科技攻关计划项目(编号:212102310036)。

摘　　要：目的评估利妥昔单抗、泽布替尼与维奈克拉联合治疗弥漫性大B细胞淋巴瘤(DLBCL)的安全性和有效性。方法回顾浙江大学医学院附属第一医院于2021年4月~2024年4月收治的接受利妥昔单抗、泽布替尼和维奈克拉联合方案治疗的7例DLBCL患者的病例资料。追踪随访,评估疗效及药物不良反应。结果7例患者中,男2例,女5例,中位年龄76岁。随访9~38个月(中位时间14个月),在治疗2~3个疗程后的首次评估中,5例达到部分缓解(PR),2例达到完全缓解(CR);后续随访中,6例患者病情稳定,1例在治疗9个月时疾病进展,26个月时死亡。预估平均总生存期(OS)为32个月,平均无进展生存期(PFS)为33.8个月。常见的不良反应为1~4级血液学毒性。结论利妥昔单抗、泽布替尼与维奈克拉作为三靶点、免化疗靶治疗联合方案,在既往接受治疗或新发高龄DLBCL患者中具有较高的缓解率和良好的耐受性。Objective To evaluate the safety and efficacy of the combined therapy with rituximab,zanubrutinib,and venetoclax for the treatment of diffuse large B-cell lymphoma(DLBCL).Methods We retrospectively reviewed the medical records of 7 patients with DLBCL who were treated with a regimen including rituximab,zanubrutinib,and venetoclax at the First Affiliated Hospital of Zhejiang University School of Medicine from Apr 2021 to Apr 2024.Follow-up was conducted to assess the therapeutic outcomes and adverse drug reactions.Results Among the 7 patients,there were 2 males and 5 females with a median age of 76 years old.Follow-up ranged from 9 to 38 months(median 14 months).At the first assessment after 2~3 cycles of treatment,5 patients achieved partial remission(PR)and 2 patients achieved complete remission(CR).During subsequent follow-up,the condition of 6 patients remained stable,while 1 patient exhibited progressive disease(PD)after 9 months of treatment and died due to disease progression at 26 months.The estimated average overall survival(OS)was 32 months,and the estimated average progression-free survival(PFS)was 33.8 months.Common adverse reactions included hematologic toxicities grades 1 to 4.Conclusion The combination of rituximab,zanubrutinib,and venetoclax as a triple-target,chemotherapy-free therapeutic strategy shows a high response rate and good tolerance for patients with DLBCL,including those who have previously received treatment or are newly diagnosed elderly patients.

关 键 词：弥漫性大B细胞淋巴瘤 维奈克拉 泽布替尼 利妥昔单抗 

分 类 号：R73[医药卫生—肿瘤]